Avery, Kerry N. L.
Blazeby, Jane M.
Chalmers, Katy A.
Batchelor, Timothy J. P.
Casali, Gianluca
Internullo, Eveline
Krishnadas, Rakesh
Evans, Clare
West, Doug
Funding for this research was provided by:
Royal College of Surgeons of England Bristol Surgical Trials Centre
JB holds an NIHR Senior Investigator award (NF-SI-0514_10114)
National Institute for Health Research (NIHR) Biomedical Research Centre at UHBT and the University of Bristol (BRC-1215-20011)
Above and Beyond, the Official Charity of UHBT (2012-13-02)
Medical Research Council ConDuCT-II (Collaboration and innovation for DIfficult and Complex randomised controlled Trials In Invasive procedures) Hub for Trials Methodology Research (MR/K025643/1)
Article History
Received: 3 July 2019
First Online: 1 December 2019
Disclosures
: DW declares grants for travel expenses from GlaxoSmithKline and grants from Above and Beyond (official charity of UHBT) during the conduct of the study. DW is a member of the NHS England Clinical Expert Group on Lung Cancer (which develops commissioning guidance for lung cancer services within NHS England), Vice Chair for the Lung Cancer Guideline Update Committee 2018 (National Institute for Health and Care Excellence) and Audit Lead for Thoracic Surgery (Society for Cardiothoracic Surgery in Britain and Ireland). DW is a member of the Cardiothoracic Specialty Specific Group, Royal College of Surgeons of Edinburgh, advising the latter on issues related to cardiothoracic surgery. DW and TB declare personal fees from AstraZeneca, Johnson and Johnson, and Medtronic outside the submitted work. TB also declares personal fees from Medela. All other authors report no conflicts of interest, financial or otherwise, with respect to this work.